Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

Search Again »

Abstract Number: 0618 • ACR Convergence 2024
Comparison of Cell Type-Specific Polygenic Risk in Systemic Lupus Erythematosus Patient and Healthy Controls
Liyoung Kim¹, Vitor Aguiar², Daniela Fernandez-Salinas³, Jeffrey Sparks⁴, Peter Nigrovic¹, Joyce Chang² and Maria Gutierrez-Arcelus², ¹Boston Children's Hospital, Brookline, MA, ²Boston Children's Hospital, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Polygenic risk scores quantify the composite impact of numerous genetic variants to predict disease risk. However, conventional polygenic risk scores have limitations in revealing…
Abstract Number: 0843 • ACR Convergence 2024
External Validation and Extension of Population-Based Systemic Lupus Erythematosus Risk Prediction Models Using Genetics, and Lifestyle and Environmental Factors
Jacob J.E. Koopman¹, Jing Cui¹, Hongshu Guan¹, Emma Stevens¹, Emily Oakes¹ and Karen Costenbader², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: Many genetic and environmental risk factors for SLE are now known. We have developed SLE risk prediction models, incorporating known genetic, lifestyle, and environmental…
Abstract Number: 1094 • ACR Convergence 2024
Longitudinal Analysis of Serum Urate in Prediabetic Phase
Javier Marrugo¹, Leah Santacroce¹, Misti Paudel², Sho Fukui³, Sara Tedeschi¹ and Daniel Solomon⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital, Newton, MA
Background/Purpose: More than 460 million people worldwide are currently living with prediabetes, a condition that not only predisposes individuals to diabetes (DM) but also to…
Abstract Number: 1360 • ACR Convergence 2024
Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment
Urbano Sbarigia¹, Jing Zhao², Jackie Kwong², Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ²Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Despite scientific advances and the availability of new treatments for rheumatoid arthritis (RA), many RA patients still cannot achieve the therapeutic goal of low…
Abstract Number: 1534 • ACR Convergence 2024
Use and Safety of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients with Lupus Nephritis and Clinical Indications
April Jorge¹, Kila Panchot², Baijun Zhou², Aakash Patel¹ and Hyon K. Choi³, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have nephroprotective and cardioprotective benefits and may have a role in lupus nephritis (LN) treatment. 2023 EULAR SLE treatment guidelines…
Abstract Number: 1743 • ACR Convergence 2024
What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?
Jing Zhao¹, Urbano Sbarigia², Jackie Kwong¹, Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend low disease activity (LDA) as initial treatment goal with remission as a subsequent target whenever possible.…
Abstract Number: 2024 • ACR Convergence 2024
Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis
Chio Yokose¹, saiajay chigurupati², Bohang Jiang², Kiara Tan², Natalie McCormick² and Hyon K. Choi³, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Hypertension is the most common comorbidity among patients with gout, with a prevalence of nearly 75% among patients with gout. Losartan and calcium channel…
Abstract Number: 2224 • ACR Convergence 2024
Age of Onset of Rheumatoid Arthritis and Radiographic Changes
Masaru Shimizu¹, Misti Paudel², Nancy Shadick³, Michael Weinblatt⁴ and Daniel Solomon⁵, ¹University of Tsukuba, Yokohama, Kanagawa, Japan, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Brigham and Women's Hospital, Newton, MA

Background/Purpose: Epidemiological studies have shown that the age of onset for rheumatoid arthritis (RA) is increasing. However, associations between age of onset and joint erosion…
Abstract Number: 0034 • ACR Convergence 2023
Genome-Wide Association Study for Loci Associated with Positive Antinuclear Antibodies in a Large Hospital Biobank
Jing Cui¹, Jeong Yee², Liming Liang³, Jack Ellrodt², Emily G. Oakes², Hongshu Guan² and Karen Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Antinuclear antibodies (ANA) to intranuclear particles are found in the blood of people with and without autoimmune diseases. To our knowledge, only 1 past…
Abstract Number: 0221 • ACR Convergence 2023
Post-COVID-19 Autoimmune Serologies and Immunophenotypes
Emily G. Oakes¹, Katherine Buhler², Ifeoluwakiisi Adejoorin¹, Kathryne Marks¹, Eilish Dillon¹, Jack Ellrodt¹, Jeong Yee¹, Deepak Rao¹, May Choi³ and Karen Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²University of Calgary; Cumming School of Medicine, Calgary, AB, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Autoimmunity after COVID-19 infection has been reported. We examined connective tissue disease (CTD) symptoms and autoantibodies, SARS-CoV-2 serologies, and T and B cell immunophenotypes…
Abstract Number: 0339 • ACR Convergence 2023
Longitudinal Glucocorticoid Toxicity in Rheumatic Disease Patients (LONG-TOX) and Associations with Quality of Life and Healthcare Resource Utilization: Interim Analysis from a Prospective Cohort
Naomi Patel¹, Aubree McMahon¹, Grace McMahon¹, Sebastian Perez-Espina¹, Isha Jha¹, Adam Jarvie¹ and John Stone², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: Glucocorticoids (GCs) continue to be the cornerstone of therapy for many rheumatic diseases, though long-term exposure to GCs has been linked to dozens of…
Abstract Number: 0744 • ACR Convergence 2023
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus
May Choi¹, Hongshu Guan², Kazuki Yoshida³, Benjamin Kargere⁴, Jack Ellrodt⁵, Emma Stevens², Tianrun Cai², Brendan Everett², Brittany Weber² and Karen Costenbader⁶, ¹University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital, Boston, MA, ³Takeda, Boston, MA, ⁴Williams College, Boston, MA, ⁵Williams College, Williamstown, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) risk is elevated in patients with SLE but underestimated by current general population prediction algorithms that do not include SLE-related variables.…
Abstract Number: 1003 • ACR Convergence 2023
A Multidisciplinary Obstetric-Medicine/Rheumatology Specialty Clinic in the United States: A Five Year Analysis
Griffin Reed¹, Joyce Mathew¹, Kelsey Rigby², Mery Deeb³, Elena Cravens¹, Anthony Reginato⁴, Gofran Tarabulsi⁵ and Joanne Cunha⁶, ¹Brown University, Providence, RI, ²Dartmouth Hitchcock Medical Center, Falmouth, MA, ³Brown University, Warwick, RI, ⁴The Warren Alpert Medical School of Brown University, Providence, RI, ⁵Women and Infants Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, ⁶The Warren Alpert Medical School of Brown University, Riverside, RI
Background/Purpose: Rheumatic disorders frequently affect women of childbearing age. These diseases and medications used to treat them can have adverse effects on fertility and fetuses.…
Abstract Number: 1023 • ACR Convergence 2023
Characterization of Phenotypic Differences in IgG4-Related Disease Across the Sexes
Grace McMahon¹, Isha Jha¹, Aubree McMahon¹, Ana Fernandes¹, Zachary Wallace², Guy Katz¹, Cory Perugino¹ and John Stone³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a multi-organ fibroinflammatory disease with an autoimmune basis that can affect essentially any organ. Differences in phenotypic expression between males…
Abstract Number: 1116 • ACR Convergence 2023
The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System
Chio Yokose¹, Baijun Zhou¹, Natalie McCormick¹, Sruthi Tanikella¹, Minna Kohler², Janeth Yinh¹, Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: A substantial proportion of gout patients have type 2 diabetes (T2DM), heart failure (HF), and chronic kidney disease (CKD), for which SGLT2i treatment is…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].